Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

707
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
707
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

871
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
871
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
615

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case Report of Valacyclovir-Associated Neurotoxicity.

Microorganisms·2026
Same author

Medication-Related Safety Events.

Joint Commission journal on quality and patient safety·2025
Same author

Novel Antibiotics: Niches, Efficacies, and Clinical Pearls.

Journal of infusion nursing : the official publication of the Infusion Nurses Society·2025
Same author

The family medicine accelerated track at Texas Tech University Health Sciences Center: results from a 10-year program to bend the primary care curve.

Medical education online·2025
Same author

Getting to the Bottom of a Patient's Penicillin Allergy Label.

Journal of infusion nursing : the official publication of the Infusion Nurses Society·2025
Same author

Corticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease.

American journal of medicine open·2024
Same journal

Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital.

Drug safety - case reports·2019
Same journal

Fournier's Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report.

Drug safety - case reports·2019
Same journal

A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy.

Drug safety - case reports·2019
Same journal

Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.

Drug safety - case reports·2019
Same journal

Allopurinol-Induced Toxic Epidermal Necrolysis.

Drug safety - case reports·2019
Same journal

Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report.

Drug safety - case reports·2019
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Linezolid-Associated Hypoglycemia.

Herman Joseph Johannesmeyer1, Suhani Bhakta2, Felix Morales3

  • 1Pharmacy Practice, College of Pharmacy, Marshall B. Ketchum University, Fullerton, USA.

Drug Safety - Case Reports
|November 11, 2017
PubMed
Summary
This summary is machine-generated.

Linezolid, an antibiotic, can cause severe hypoglycemia (low blood sugar) in patients. This case highlights the importance of monitoring blood glucose levels during linezolid therapy, especially in elderly patients.

More Related Videos

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.6K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.4K

Related Experiment Videos

Last Updated: Feb 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.6K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.4K

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Internal Medicine

Background:

  • Recurrent hypoglycemia can lead to emergency department visits and hospitalizations.
  • Linezolid is an antibiotic used for serious infections, including those caused by Gram-positive bacteria.
  • Drug-induced hypoglycemia is a potential adverse effect of various medications.

Purpose of the Study:

  • To report a case of severe hypoglycemia associated with linezolid therapy.
  • To emphasize the importance of recognizing and managing drug-induced hypoglycemia.
  • To contribute to the understanding of linezolid's adverse effect profile.

Main Methods:

  • A case report of a 77-year-old male patient treated with linezolid for a Staphylococcus hominis urinary tract infection.
  • Clinical observation of recurrent hypoglycemic episodes during linezolid therapy.
  • Discontinuation of linezolid and monitoring of blood glucose levels.
  • Assessment of causality using the Naranjo scale.

Main Results:

  • The patient experienced recurrent, severe hypoglycemic episodes starting 9.5 days into linezolid treatment.
  • Hypoglycemia persisted despite dextrose administration and resolved after linezolid discontinuation.
  • The Naranjo scale indicated a possible to probable causal relationship between linezolid and hypoglycemia.
  • The patient had no further blood glucose complications after discontinuation.

Conclusions:

  • Linezolid can cause significant hypoglycemia, potentially requiring prolonged monitoring and management.
  • Clinicians should maintain a high index of suspicion for drug-induced hypoglycemia in patients on linezolid.
  • Further research may be warranted to elucidate the mechanism of linezolid-induced hypoglycemia.